Fig. 7: Protective efficacy of CF501/RBD-Fc in rhesus macaques. | Cell Research

Fig. 7: Protective efficacy of CF501/RBD-Fc in rhesus macaques.

From: A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

Fig. 7

a Immunization and challenge procedures for rhesus macaques. Rhesus macaques were immunized with CF501/RBD-Fc and Alum/RBD-Fc on day 0, 21, and 115, respectively. The control group was treated with an equal volume of PBS. The SARS-CoV-2 (Strain: WH-09) challenge was conducted on day 223. Nasal swabs were collected at 3, 5, and 7 dpc. Macaques were sacrificed at 7 dpc. Tissues, such as lungs and nasal turbinate, were collected. b SARS-CoV-2 viral loads in the nasal swabs at 3, 5, and 7 dpc were determined using RT-qPCR assay. Bold lines reflect mean values. c Peak viral loads in nasal swabs after challenge. d SARS-CoV-2 viral loads in the indicated lung lobes from macaques at 7 dpc were determined using RT-qPCR assay. e, f SARS-CoV-2 viral loads in nasal turbinate (e) and nasal mucosa (f) from macaques at 7 dpc. g Histopathological staining of the lungs from macaques at 7 dpc. The dotted line represents the limit of detection. Statistical analyses were performed using two-way ANOVA for (d). Statistical analyses for (c), (e), and (f) were performed using one-way ANOVA. *P < 0.05, **P < 0.001, ***P < 0.0001.

Back to article page